Importantly, IGN523, a humanized anti-CD98 (anti-SLC3A2) monoclonal antibody has been tested for relapsed or refractory acute myeloid leukemia, and preclinical data showed effective anti-tumor activity in xenograft models (173). This evidence concerns the gene SLC3A2 and neoplasm.